ПРОГНОЗ ВЫЖИВАЕМОСТИ ПОЧЕЧНОГО ТРАНСПЛАНТАТА: ИММУНОЛОГИЧЕСКИЙ РИСК И ТИП ОТТОРЖЕНИЯ
Аннотация
Об авторах
М. С. ХраброваРоссия
В. А. Добронравов
Россия
А. В. Набоков
Россия
Х. -Й. Грене
Россия
М. . Халленслебен
Россия
А. В. Смирнов
Россия
Ф. . Клим
Россия
Список литературы
1. Pesavento TE. Kidney Transplantation in the Context of Renal Replacement Therapy. Clin J Am Soc Nephrol 2009; 4: 2035-2039
2. Tonelli M, Wiebe N, Knoll G et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 2011; 11 (10): 2093-2109
3. El-Zoghby ZM, Stegall MD, Lager DJ et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9 (3): 527-535
4. Naesens M, Kuypers DR, De Vusser K et al. The histology of kidney transplant failure: a long-term follow-up study. Transplantation 2014; 98 (4): 427-435
5. Pallardó M, Sancho CA, Capdevila PL, Franco EA. Acute rejection and late renal transplant failure: risk factors and prognosis. Nephrol Dial Transplant 2004; 19 [Suppl 3]: 38-42
6. Filippone EJ, Farber JL. The specificity of acute and chronic microvascular alterations in renal allografts. Clin Transplant2013; 27 (6): 790-798
7. Sellares J, Freitasa DG, Mengela M et al. Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and Nonadherence. Am J Transplant 2012; 12: 388-399
8. Fidler SJ, Irish AB, Lim W et al. Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death. Transpl Immunol 2013; 28 (4): 148-153
9. Dunn TB, Noreen H, Gillingham K et al. Revisiting Traditional Risk Factors for Rejection and Graft Loss After Kidney Transplantation. Am J Transplant 2011; 11: 2132-2143
10. Loupy A, Suberbielle-Boissel C, Hill GS et al. Outcome of Subclinical Antibody-Mediated Rejection in Kidney Transplant Recipients with Preformed Donor-Specific Antibodies. Am J Transplant 2009; 9: 2561-2570
11. Ledesma-Gumba MA, Danguilan RA, Casasola CC, Ona ET. Efficacy of risk stratification in tailoring immunosuppression regimens in kidney transplant patients at the national kidney and transplant institute. Transplant Proc 2008; 40 (7): 2195-2197
12. Diet C, Audard V, Roudot-Thoraval F et al. Immunological risk in recipients of kidney transplants from extended criteria donors. Nephrol Dial Transplant 2010; 25: 2745-2753
13. Noël C, Abramowicz D, Durand D et al. Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients. JASN 2009; 20: 1385-1392
14. van Gelder T, Tedesco Silva H, de Fijter JW et al. Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. Transplantation 2010; 89 (5): 595-599
15. High Risk Renal Transplant Consensus Group. Defining high risk in adult kidney transplantation. Prog Transplant 2009; 19 (3): 252-258
16. Nascimento E, Fabreti de Oliveira RA, Maciel MD et al. Kidney Transplantation: Evaluation and Clinical Outcome of 237 Recipients at Low, Medium, High, or Strong Immunological Risk of Rejection. Transplant P 2014; 46: 101-107
17. Tait BD, Süsal C, Gebel HM et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95 (1): 19-47
18. Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant 2009; 9 [Suppl 3]: 1-155
19. Общероссийская общественная организация трансплантологов «Российское трансплантологическое общество». Национальные клинические рекомендации «Трансплантация почки» 2013 г. http://transpl.ru/specialist/rto, http:// transpl.ru/images/cms/data/pdf/nacional_nye_klinicheskie_reko-mendacii_po_transplantacii_pochki.pdf.
20. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55 (2): 713-723
21. Haas M, Sis B, Racusen LC et al. Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions. Am J Transplant 2014; 14: 272-283
22. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130(6): 461-470
23. Lim WH, Chapman JR, Wong G. Peak Panel Reactive Antibody, Cancer, Graft, and Patient Outcomes in Kidney Transplant Recipients. Transplantation 2014; Dec 23 [Epub ahead of print]
24. Kaczmarczyk M, Kotfis K, Biernawska J et al. Effect of recipient sensitization (peak panel reactive antibodies) on 15-year survival after kidney transplantation. Transplant Proc 2014; 46 (8): 2699-2702
25. Opelz G, Döhler B, Ruhenstroth A et al. The collaborative transplant study registry. Transplant Rev (Orlando) 2013; 27 (2): 43-45
26. Süsal C, Döhler B, Opelz G. Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. Hum Immunol 2009; 70 (8): 569-573
27. Абрамов ВЮ, Мойсюк ЯГ, Калужина НН, Богданова НБ. Дифференцированное влияние совместимости по HLA-A, HLA-B и HLA-DR на выживаемость аллотрансплантата почки. Вест трансплантологии и искусственных органов 2012; 3: 19
28. Süsal C, Döhler B, Opelz G. Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. Hum Immunol 2009; 70 (8): 569-573
29. Dinis P, Nunes P, Marconi L et al. Kidney retransplantation: removal or persistence of the previous failed allograft? Transplant Proc 2014; 46 (6): 1730-1734
30. CTS http://www.ctstransplant.org/public/graphics/ sample.shtml
31. Hung SY , Lin TM, Chang MY et al. Risk factors of sensitization to human leukocyte antigen in end-stage renal disease patients. Hum Immunol2014; 75 (6): 531-535
32. Fidler S, Swaminathan R, Lim W et al. Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss. Transpl Immunol 2013; 29 (1-4): 22-27
33. Lebranchu Y, Baan C, Biancone L et al. Pretransplant identification of acute rejection risk following kidney transplantation. Transpl Int 2014. 27 ( 2): 129-138
34. Tsapepas DS, Vasilescu R, Tanriover B et al. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation. Transplantation 2014; 97 (6): 642-647
35. Lefaucheur C, Suberbielle-Boissel C, Hill GS et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8 (2): 324-331
36. Mohan S, Palanisamy A, Tsapepas D et al. Donor-specific antibodies adversely affect kidney allograft outcomes. Am Soc Nephrol 2012; 23 (12): 2061-2071
37. Marfo K, Ajaimy M, Colovai A et al. Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies. Transplantation 2014; 98 (10): 1082-1088
38. de Souza PS, David-Neto E, Panajotopolous N et al. Dynamics of anti-human leukocyte antigen antibodies after renal transplantation and their impact on graft outcome. Clin Transplant 2014; 28 (11): 1234-1243
39. Ginevri F, Nocera A, Comoli P et al. Posttransplant De Novo Donor-Specific HLA Antibodies Identify Pediatric Kidney Recipients at Risk for Late Antibody-Mediated Rejection. Am J Transplant 2012; 12 (12): 3355-3362
40. Malheiro J, Tafulo S, Dias L et al. Posttransplant allosen-sitization in low immunological risk kidney and kidney-pancreas graft recipients. Biomed Res Int 2014; 2014: 438945
41. de Kort H, Willicombe M, Brookes P et al. Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am J Transplant 2013; 13 (2): 485-492
42. Buob D, Grimbert P, Glowacki F et al. Three-year outcome of isolated glomerulitis on 3-month protocol biopsies of donor HLA antibody negativepatients. Transpl Int 2012; 25 (6): 663-670
43. Einecke G, Sis B, Reeve J et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9 (11): 2520-2531
44. Nabokow A, Dobronravov VA, Khrabrova M et al. Long-term kidney allograft survival in patients with transplant glomerulitis. Transplantation 2015; 99 (2): 331-339
Рецензия
Для цитирования:
Храброва М.С., Добронравов В.А., Набоков А.В., Грене Х.-., Халленслебен М., Смирнов А.В., Клим Ф. ПРОГНОЗ ВЫЖИВАЕМОСТИ ПОЧЕЧНОГО ТРАНСПЛАНТАТА: ИММУНОЛОГИЧЕСКИЙ РИСК И ТИП ОТТОРЖЕНИЯ. Нефрология. 2015;19(4):41-50.
For citation:
Khrabrova M., Dobronravov V.A., Nabokow A., Gröne H.-., Hallensleben M., Smirnov A.V., Kliem V. PROGNOSIS OF KIDNEY ALLOGRAFT SURVIVAL: IMMUNOLOGICAL RISK AND REJECTION TYPE. Nephrology (Saint-Petersburg). 2015;19(4):41-50. (In Russ.)